vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and CARTERS INC (CRI). Click either name above to swap in a different company.

Astrana Health, Inc. is the larger business by last-quarter revenue ($950.5M vs $757.8M, roughly 1.3× CARTERS INC). CARTERS INC runs the higher net margin — 1.5% vs 0.7%, a 0.8% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -0.1%). Astrana Health, Inc. produced more free cash flow last quarter ($-6.0M vs $-144.1M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.

ASTH vs CRI — Head-to-Head

Bigger by revenue
ASTH
ASTH
1.3× larger
ASTH
$950.5M
$757.8M
CRI
Growing faster (revenue YoY)
ASTH
ASTH
+43.0% gap
ASTH
42.9%
-0.1%
CRI
Higher net margin
CRI
CRI
0.8% more per $
CRI
1.5%
0.7%
ASTH
More free cash flow
ASTH
ASTH
$138.1M more FCF
ASTH
$-6.0M
$-144.1M
CRI

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASTH
ASTH
CRI
CRI
Revenue
$950.5M
$757.8M
Net Profit
$6.6M
$11.6M
Gross Margin
45.1%
Operating Margin
1.9%
3.8%
Net Margin
0.7%
1.5%
Revenue YoY
42.9%
-0.1%
Net Profit YoY
184.4%
-80.1%
EPS (diluted)
$0.12
$0.32

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
CRI
CRI
Q4 25
$950.5M
Q3 25
$956.0M
$757.8M
Q2 25
$654.8M
$585.3M
Q1 25
$620.4M
$629.8M
Q4 24
$665.2M
Q3 24
$478.7M
Q2 24
$486.3M
Q1 24
$404.4M
Net Profit
ASTH
ASTH
CRI
CRI
Q4 25
$6.6M
Q3 25
$373.0K
$11.6M
Q2 25
$9.4M
$446.0K
Q1 25
$6.7M
$15.5M
Q4 24
$-7.8M
Q3 24
$16.1M
Q2 24
$19.2M
Q1 24
$14.8M
Gross Margin
ASTH
ASTH
CRI
CRI
Q4 25
Q3 25
45.1%
Q2 25
48.1%
Q1 25
46.2%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ASTH
ASTH
CRI
CRI
Q4 25
1.9%
Q3 25
2.0%
3.8%
Q2 25
3.1%
0.7%
Q1 25
3.3%
4.1%
Q4 24
0.1%
Q3 24
5.9%
Q2 24
6.2%
Q1 24
7.5%
Net Margin
ASTH
ASTH
CRI
CRI
Q4 25
0.7%
Q3 25
0.0%
1.5%
Q2 25
1.4%
0.1%
Q1 25
1.1%
2.5%
Q4 24
-1.2%
Q3 24
3.4%
Q2 24
3.9%
Q1 24
3.7%
EPS (diluted)
ASTH
ASTH
CRI
CRI
Q4 25
$0.12
Q3 25
$0.01
$0.32
Q2 25
$0.19
$0.01
Q1 25
$0.14
$0.43
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
CRI
CRI
Cash + ST InvestmentsLiquidity on hand
$429.5M
$184.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$864.6M
Total Assets
$2.2B
$2.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
CRI
CRI
Q4 25
$429.5M
Q3 25
$463.4M
$184.2M
Q2 25
$342.1M
$338.2M
Q1 25
$260.9M
$320.8M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Stockholders' Equity
ASTH
ASTH
CRI
CRI
Q4 25
$779.3M
Q3 25
$775.5M
$864.6M
Q2 25
$765.5M
$853.9M
Q1 25
$745.4M
$847.2M
Q4 24
$712.7M
Q3 24
$704.6M
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
ASTH
ASTH
CRI
CRI
Q4 25
$2.2B
Q3 25
$2.2B
$2.5B
Q2 25
$1.4B
$2.5B
Q1 25
$1.3B
$2.3B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
CRI
CRI
Operating Cash FlowLast quarter
$-2.9M
$-128.0M
Free Cash FlowOCF − Capex
$-6.0M
$-144.1M
FCF MarginFCF / Revenue
-0.6%
-19.0%
Capex IntensityCapex / Revenue
0.3%
2.1%
Cash ConversionOCF / Net Profit
-0.44×
-11.04×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
CRI
CRI
Q4 25
$-2.9M
Q3 25
$10.0M
$-128.0M
Q2 25
$90.9M
$40.3M
Q1 25
$16.6M
$-48.6M
Q4 24
$-10.9M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$6.0M
Free Cash Flow
ASTH
ASTH
CRI
CRI
Q4 25
$-6.0M
Q3 25
$7.4M
$-144.1M
Q2 25
$89.5M
$24.1M
Q1 25
$13.6M
$-59.0M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
CRI
CRI
Q4 25
-0.6%
Q3 25
0.8%
-19.0%
Q2 25
13.7%
4.1%
Q1 25
2.2%
-9.4%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
CRI
CRI
Q4 25
0.3%
Q3 25
0.3%
2.1%
Q2 25
0.2%
2.8%
Q1 25
0.5%
1.6%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
CRI
CRI
Q4 25
-0.44×
Q3 25
26.69×
-11.04×
Q2 25
9.65×
90.37×
Q1 25
2.48×
-3.13×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

CRI
CRI

Sales Channel Directly To Consumer$362.3M48%
Sales Channel Through Intermediary$283.8M37%
Other$110.4M15%
Gift Cards$1.3M0%

Related Comparisons